Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors

Julie N. Graff, Celestia S. Higano, Noah M. Hahn, Matthew H. Taylor, Bin Zhang, Xiaofei Zhou, Karthik Venkatakrishnan, E. Jane Leonard, John Sarantopoulos

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Fingerprint

Dive into the research topics of 'Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences